Coeptis Therapeutics Holdings (COEP) has released an update to notify the public and investors about listing compliance status.
Coeptis Therapeutics Holdings, Inc. has been notified by Nasdaq that it no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company’s stock must maintain a closing bid price of at least $1.00 per share, which it failed to do over the past 30 business days. Nasdaq has allowed a 180-day compliance period until July 29, 2024, for the company to meet this requirement, with the possibility of a second 180-day period if necessary conditions are met. The company’s listing remains effective during this period, and it plans to monitor its stock price to regain compliance with Nasdaq’s requirements. Failure to regain compliance may lead to delisting, but the company would have the right to appeal the decision.
For further insights into COEP stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
